We are international
• treatment options TEXT SIZE   
Novel Therapies

Pomalyst® is the newest oral immun­omodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.

Pomalyst® (pomalidomide) capsules

01.21.16   Long Exposure of Pomalidomide May Be Safe for R/R Myeloma
Pomalidomide and dexamethasone favored prolonged and safe exposure to treatment patients with heavily treated and end-stage relapsed/refractory multiple myeloma, a study published online ahead of print in the journal Annals of Oncology has shown.

02.25.13   Understanding Pomalyst®
(pomalidomide) capsules

This booklet is about a drug that is used only for patients with relapsed and refractory myeloma. It pres­ents information on Pomalyst® and how it works, the results of clinical trials and ongoing research with Pomalyst, how and when to take Pomalyst, and its possible side effects and how to manage them. 

03.31.16   Pomalidomide-based triplet effective in relapsed, refractory myeloma
The addition of cyclophosphamide to pomalidomide and dexamethasone prolonged PFS and resulted in a superior overall response rate in patients with relapsed or refractory multiple myeloma, according to the results of a phase 2 study.

02.25.13   Pomalyst® (pomalidomide) capsules Tip Card

12.01.09   Pomalidomide on clinicaltrials.gov
Like lenalidomide, pomalidomide is an immunomodulatory derivative (IMiD) of thalidomide. Approved by the FDA in 2013, alone and in combination with other drugs, it is showing clinical activity and is well-tolerated in patients who have relapsed after multiple prior therapies and are refractory to both lenalidomide and bortezomib.